Symbion Capitulates, Nearing End To Primary’s Takeover Of Australian Health Care Giant
This article was originally published in PharmAsia News
Executive Summary
The months-long battle between Australia's giant health care companies appeared near an end when Primary Healthcare said it had won control of a majority of Symbion Healthcare. The Symbion board capitulated in the battle and recommended shareholders accept the buyout when Primary gained 50.1 percent of the shares. Among the businesses at sake is Symbion's pharmacy business. (Click here for more
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.